Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include...

Ogkologos - 25 Απριλίου, 2025

What’s at the Root of Ovarian Cancer? New Study May Have...

Ogkologos - 24 Απριλίου, 2025

EMA Recommends Extension of Indications for Pirtobrutinib

Ogkologos - 24 Απριλίου, 2025

Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the...

Ogkologos - 23 Απριλίου, 2025

Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients...

Ogkologos - 23 Απριλίου, 2025

Potential for Larger Gene Panels to Increase the Number of Molecularly...

Ogkologos - 22 Απριλίου, 2025

FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of...

Ogkologos - 18 Απριλίου, 2025

Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

Ogkologos - 18 Απριλίου, 2025

EMA Recommends Extension of Indications for Glofitamab

Ogkologos - 17 Απριλίου, 2025

Cancer Mortality Prediction for 2025 Continues to Show Favourable Trends In...

Ogkologos - 16 Απριλίου, 2025

1...515253...440 Σελίδα 52 από 440

MOST POPULAR

Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC...

19 Δεκεμβρίου, 2023

Cancer Research UK’s charity Christmas cards now available

28 Οκτωβρίου, 2021

DNA from Ancient Viruses Helps Many Cancers Grow

6 Σεπτεμβρίου, 2024

20 years on: how we’ve decreased cancer death rates

17 Δεκεμβρίου, 2022

Φόρτωση περισσοτέρων

FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include...

What’s at the Root of Ovarian Cancer? New Study May Have...

EMA Recommends Extension of Indications for Pirtobrutinib

Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the...

Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients...

Potential for Larger Gene Panels to Increase the Number of Molecularly...

FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of...

Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

EMA Recommends Extension of Indications for Glofitamab

Cancer Mortality Prediction for 2025 Continues to Show Favourable Trends In...

MOST POPULAR

Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC...

Cancer Research UK’s charity Christmas cards now available

DNA from Ancient Viruses Helps Many Cancers Grow

20 years on: how we’ve decreased cancer death rates

HOT NEWS

England: Smoking responsible for twice as many cancers in most deprived...

In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer

Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients...

Job Loss During Cancer: How to Cope and Continue Treatment

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ